Jefferies confirms its Buy rating on Biogen shares, with an unchanged price target of $285.

The analyst reports that a meeting is scheduled today with the European Medicines Agency on Leqembi (a drug to treat Alzheimer's disease), and that a CHMP opinion could be published by the end of the week.

Jefferies estimates that consensus models predict an 80-90% probability of approval in the EU.

'Overall, the efficacy data from the Phase III study were strong, so we don't expect global approval to be a driver of questions', notes the broker.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.